2002-2008年在巴西Brasília接受高活性抗逆转录病毒治疗的艾滋病毒/艾滋病患者病毒学失败的预测因素

IF 2 Q3 PHARMACOLOGY & PHARMACY
Drug Target Insights Pub Date : 2011-01-01 Epub Date: 2011-11-24 DOI:10.4137/DTI.S7527
Edson José Monteiro Bello, Amabel Fernandes Correia, José Ricardo Pio Marins, Edgar Merchan-Hamann, Luis Isamu Barros Kanzaki
{"title":"2002-2008年在巴西Brasília接受高活性抗逆转录病毒治疗的艾滋病毒/艾滋病患者病毒学失败的预测因素","authors":"Edson José Monteiro Bello,&nbsp;Amabel Fernandes Correia,&nbsp;José Ricardo Pio Marins,&nbsp;Edgar Merchan-Hamann,&nbsp;Luis Isamu Barros Kanzaki","doi":"10.4137/DTI.S7527","DOIUrl":null,"url":null,"abstract":"<p><p>Little data exists concerning the efficacy of the antiretroviral therapy in the Federal District in Brazil, therefore in order to improve HIV/AIDS patients' therapy and to pinpoint hot spots in the treatment, this research work was conducted. Of 139 HIV/AIDS patients submitted to the highly active antiretroviral therapy, 12.2% failed virologically. The significant associated factors related to unresponsiveness to the lentiviral treatment were: patients' place of origin (OR = 3.28; IC95% = 1.0-9.73; P = 0.032) and Mycobacterium tuberculosis infection (RR = 2.90; IC95% = 1.19-7.02; P = 0.019). In the logistic regression analysis, the remaining variables in the model were: patients' birthplace (OR = 3.28; IC95% = 1.10-9.73; P = 0.032) and tuberculosis comorbidity (OR = 3.82; IC95% = 1.19-12.22; P = 0.024). The patients enrolled in this survey had an 88.0% therapeutic success rate for the maximum period of one year of treatment, predicting that T CD4(+) low values and elevated viral loads at pretreatment should be particularly considered in tuberculosis coinfection, besides the availability of new antiretroviral drugs displaying optimal activity both in viral suppression and immunological reconstitution.</p>","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"5 ","pages":"33-41"},"PeriodicalIF":2.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/DTI.S7527","citationCount":"15","resultStr":"{\"title\":\"Predictors of Virologic Failure in HIV/AIDS Patients Treated with Highly Active Antiretroviral Therapy in Brasília, Brazil During 2002-2008.\",\"authors\":\"Edson José Monteiro Bello,&nbsp;Amabel Fernandes Correia,&nbsp;José Ricardo Pio Marins,&nbsp;Edgar Merchan-Hamann,&nbsp;Luis Isamu Barros Kanzaki\",\"doi\":\"10.4137/DTI.S7527\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Little data exists concerning the efficacy of the antiretroviral therapy in the Federal District in Brazil, therefore in order to improve HIV/AIDS patients' therapy and to pinpoint hot spots in the treatment, this research work was conducted. Of 139 HIV/AIDS patients submitted to the highly active antiretroviral therapy, 12.2% failed virologically. The significant associated factors related to unresponsiveness to the lentiviral treatment were: patients' place of origin (OR = 3.28; IC95% = 1.0-9.73; P = 0.032) and Mycobacterium tuberculosis infection (RR = 2.90; IC95% = 1.19-7.02; P = 0.019). In the logistic regression analysis, the remaining variables in the model were: patients' birthplace (OR = 3.28; IC95% = 1.10-9.73; P = 0.032) and tuberculosis comorbidity (OR = 3.82; IC95% = 1.19-12.22; P = 0.024). The patients enrolled in this survey had an 88.0% therapeutic success rate for the maximum period of one year of treatment, predicting that T CD4(+) low values and elevated viral loads at pretreatment should be particularly considered in tuberculosis coinfection, besides the availability of new antiretroviral drugs displaying optimal activity both in viral suppression and immunological reconstitution.</p>\",\"PeriodicalId\":11326,\"journal\":{\"name\":\"Drug Target Insights\",\"volume\":\"5 \",\"pages\":\"33-41\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2011-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4137/DTI.S7527\",\"citationCount\":\"15\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Target Insights\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4137/DTI.S7527\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2011/11/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Target Insights","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/DTI.S7527","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2011/11/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 15

摘要

关于巴西联邦区抗逆转录病毒治疗的疗效数据很少,因此,为了改善艾滋病毒/艾滋病患者的治疗,并找出治疗中的热点,开展了这项研究工作。在139名接受高效抗逆转录病毒治疗的艾滋病毒/艾滋病患者中,12.2%的患者病毒学失败。慢病毒治疗无应答的显著相关因素为:患者原产地(OR = 3.28;Ic95% = 1.0-9.73;P = 0.032)和结核分枝杆菌感染(RR = 2.90;Ic95% = 1.19-7.02;P = 0.019)。在logistic回归分析中,模型剩余变量为:患者出生地(OR = 3.28;Ic95% = 1.10-9.73;P = 0.032)和肺结核合并症(OR = 3.82;Ic95% = 1.19-12.22;P = 0.024)。本调查纳入的患者在最长一年的治疗期间治疗成功率为88.0%,这预示着在结核病合并感染中,除了在病毒抑制和免疫重建方面均表现出最佳活性的新型抗逆转录病毒药物的可用性外,还应特别考虑T CD4(+)低值和预处理时病毒载量升高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Predictors of Virologic Failure in HIV/AIDS Patients Treated with Highly Active Antiretroviral Therapy in Brasília, Brazil During 2002-2008.

Little data exists concerning the efficacy of the antiretroviral therapy in the Federal District in Brazil, therefore in order to improve HIV/AIDS patients' therapy and to pinpoint hot spots in the treatment, this research work was conducted. Of 139 HIV/AIDS patients submitted to the highly active antiretroviral therapy, 12.2% failed virologically. The significant associated factors related to unresponsiveness to the lentiviral treatment were: patients' place of origin (OR = 3.28; IC95% = 1.0-9.73; P = 0.032) and Mycobacterium tuberculosis infection (RR = 2.90; IC95% = 1.19-7.02; P = 0.019). In the logistic regression analysis, the remaining variables in the model were: patients' birthplace (OR = 3.28; IC95% = 1.10-9.73; P = 0.032) and tuberculosis comorbidity (OR = 3.82; IC95% = 1.19-12.22; P = 0.024). The patients enrolled in this survey had an 88.0% therapeutic success rate for the maximum period of one year of treatment, predicting that T CD4(+) low values and elevated viral loads at pretreatment should be particularly considered in tuberculosis coinfection, besides the availability of new antiretroviral drugs displaying optimal activity both in viral suppression and immunological reconstitution.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Drug Target Insights
Drug Target Insights PHARMACOLOGY & PHARMACY-
CiteScore
2.70
自引率
0.00%
发文量
5
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信